* Cidara Therapeutics Inc CDTX.OQ reported a quarterly
adjusted
loss of 4 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -19 cents. The mean expectation of
four analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results to range from -16 cents
to -7 cents per share.
* Revenue rose 72.1% to $17.58 million from a year ago;
analysts
expected $11.54 million.
* Cidara Therapeutics Inc's reported EPS for the quarter was
a
loss of 4 cents.
* The company reported a quarterly loss of $3.21 million.
* Cidara Therapeutics Inc shares had fallen by 26.0% this
quarter and lost 14.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $5.50
This summary was machine generated from LSEG data April 22 at
10:11 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.10 -0.04 Beat
Sep. 30 2023 -0.16 -0.09 Beat
Jun. 30 2023 -0.13 -0.14 Missed
Mar. 31 2023 -0.04 0.03 Beat